The Company believes that the pharmaceutical sector is an attractive opportunity to potentially apply the C1 technology platform
The Company’s primary objective is to position the C1 technology as the expression platform of choice in the development and production of commercial scale biologic vaccines and drugs
C1’s HISTORICAL COMMERCIAL SUCCESS
Dyadic has developed an industrially proven expression system based on the fungus Myceliophthora thermophila, nicknamed C1. The C1 technology was previously used commercially by us, and is now being used by renowned industry leaders such as BASF, DuPont and others to develop and produce industrial products from DNA such as enzymes for a wide variety of applications and industries.
Dyadic’s C1 Expression System is an optimized and industrially proven system that turns genes into a broad range of valuable products. The C1 Technology Platform helps to overcome some of the inadequacies of existing expression technologies used for gene discovery, product development and commercialization. The patented and proprietary C1 Expression System is one of a very few commercially available solutions able to efficiently uptake genes and develop highly scalable industrial processes to produce large volumes of affordable enzymes and other protein products. This fully programmable system is robust, flexible, and safe and has produced products in some of the largest fermenters used in the biotechnology industry.
OUR VISION FOR LEVERAGING C1 INTO THE PHARMACEUTICAL INDUSTRY
The Company has long believed that the pharmaceutical field is one of the most attractive opportunities in which the C1 technology may be applied. We believe the C1 technology platform has potential to be a safe and efficient expression system that may help speed up the development and production of biologics at flexible commercial scales. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes C1 can potentially help bring biologic vaccines and drugs to market faster, in greater volumes and at lower cost to drug developers and manufacturers. This can potentially improve access and reduce costs to patients and the healthcare system, and most importantly save lives.
- Potential to improve therapeutic vaccine and drug performance
- Potential to remove a critical bottleneck in protein development and manufacturing processes
- Allows for rapid scaling
- Potential to significantly lower CapEx and OpEx
The combination of a portion of the proceeds from the DuPont transaction and additional industry and government funding that is being sought, are expected to provide Dyadic with the opportunity to accelerate further development and optimization of the C1 technology in the area of biopharmaceuticals. In addition, the unique attributes of C1 may create attractive research, licensing, collaboration and other opportunities if C1 demonstrates operational efficiencies and reduced capital requirements for biologic vaccine and drug manufacturers. In addition, the unique attributes of C1 may create attractive research, licensing, collaboration and other opportunities, if C1 demonstrates operational efficiencies and reduced capital requirements for biologic vaccines and drug manufacturers.
Dyadic is one of a consortium of companies participating in the EU sponsored ZAPI research program. ZAPI is a program sponsored by the EU suitable for the rapid development and production of vaccines and protocols to fast-track registration of developed products to combat epidemic zoonotic diseases that have the potential to effect the human population.
We achieved encouraging results, knowledge and experience in vaccine development from our prior research collaboration with Sanofi Pasteur (which is anticipated to end in October 2016) that we believe can be leveraged and built upon with other partners. During the collaboration, meaningful improvements were made to the C1 expression system to produce antigens of interest that Sanofi further tested in mice trials. The mice trail data indicated that the C1 produced antigen generated an equal, or better, immune response in mice than the industry standard antigen.
Looking forward, leveraging this knowledge and experience we expect to be able to generate a greater, new and enhanced interest in the C1 technology for developing and manufacturing biologic vaccines.
Additionally, internal and external research projects are underway to continue to refine the C1 technology for its potential use in developing & manufacturing new, better or more affordable vaccines, antibodies and other therapeutic proteins such as insulin and a generic version of Lucentis.
Dyadic is seeking Research collaborations, Government Funding, Partners, and sub-licensees in which to apply the C1 platform in the vaccine, antibody, biosimilar and Biobetters industries.